BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25500173)

  • 1. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013.
    Moro PL; Zheteyeva Y; Lewis P; Shi J; Yue X; Museru OI; Broder K
    Vaccine; 2015 Jan; 33(4):519-22. PubMed ID: 25500173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
    Geier DA; Geier MR
    Clin Rheumatol; 2015 Jul; 34(7):1225-31. PubMed ID: 25535199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 1990-2016.
    Moro PL; Zheteyeva Y; Barash F; Lewis P; Cano M
    Vaccine; 2018 Jan; 36(1):50-54. PubMed ID: 29174107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
    Geier DA; Geier MR
    Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016.
    Moro P; Baumblatt J; Lewis P; Cragan J; Tepper N; Cano M
    Drug Saf; 2017 Feb; 40(2):145-152. PubMed ID: 27988883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017.
    Landazabal CS; Moro PL; Lewis P; Omer SB
    Vaccine; 2019 Feb; 37(9):1229-1234. PubMed ID: 30660400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System.
    Datwani H; Moro PL; Harrington T; Broder KR
    Vaccine; 2015 Jun; 33(27):3110-3. PubMed ID: 25976546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.
    Slade BA; Leidel L; Vellozzi C; Woo EJ; Hua W; Sutherland A; Izurieta HS; Ball R; Miller N; Braun MM; Markowitz LE; Iskander J
    JAMA; 2009 Aug; 302(7):750-7. PubMed ID: 19690307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
    Vichnin M; Bonanni P; Klein NP; Garland SM; Block SL; Kjaer SK; Sings HL; Perez G; Haupt RM; Saah AJ; Lievano F; Velicer C; Drury R; Kuter BJ
    Pediatr Infect Dis J; 2015 Sep; 34(9):983-91. PubMed ID: 26107345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
    Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.
    Yih WK; Greene SK; Zichittella L; Kulldorff M; Baker MA; de Jong JL; Gil-Prieto R; Griffin MR; Jin R; Lin ND; McMahill-Walraven CN; Reidy M; Selvam N; Selvan MS; Nguyen MD
    Vaccine; 2016 Jan; 34(1):172-8. PubMed ID: 26549364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the 9-Valent Human Papillomavirus Vaccine.
    Shimabukuro TT; Su JR; Marquez PL; Mba-Jonas A; Arana JE; Cano MV
    Pediatrics; 2019 Dec; 144(6):. PubMed ID: 31740500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events following immunization in Ontario's female school-based HPV program.
    Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
    Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015.
    Moro PL; Cragan J; Tepper N; Zheteyeva Y; Museru O; Lewis P; Broder K
    Vaccine; 2016 Apr; 34(20):2349-53. PubMed ID: 27013434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
    Naleway AL; Crane B; Smith N; Daley MF; Donahue J; Gee J; Greene SK; Harrington T; Jackson LA; Klein NP; Tseng HF; Vellozzi C; Weintraub ES;
    Vaccine; 2016 Jan; 34(1):167-71. PubMed ID: 26549361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.
    Ojha RP; Jackson BE; Tota JE; Offutt-Powell TN; Singh KP; Bae S
    Hum Vaccin Immunother; 2014; 10(1):232-7. PubMed ID: 24013368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of vaccines that have been kept outside of recommended temperatures: Reports to the Vaccine Adverse Event Reporting System (VAERS), 2008-2012.
    Hibbs BF; Miller E; Shi J; Smith K; Lewis P; Shimabukuro TT
    Vaccine; 2018 Jan; 36(4):553-558. PubMed ID: 29248264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.